Orchard Therapeutics plc announced the appointment of Francis Pang as vice president of global market access. Mr. Pang will be responsible for developing and executing on global pricing and market access strategies to ensure that Orchards ex vivo autologous hematopoietic stem cell (HSC) gene therapies, if approved, are reimbursed by healthcare systems worldwide. The position of vice president of global market access is a newly created position established to support the company's global expansion. Mr. Pang will report to Jason Meyenburg, chief commercial officer at Orchard. Most recently, Mr. Pang was global head of market access at Amicus Therapeutics, where he helped achieve broad reimbursement for an oral treatment for Fabry Disease in more than 20 markets worldwide.